The Great Disruption: how Chinese assets will reshape drug development
Chinese biopharma companies are at an inflection point, with rapidly advancing in science, know-how, + talent. Chinese assets are poised to reshape drug development.
Mother-Son Duo Offer Biopharma KOL Mapping with Adnexi CEO Sandra Shpilberg
Sandra Shpilberg, Co-founder and CEO of Adnexi, discusses using AI to develop effective strategies for biopharma key expert and digital opinion leader selection to elevate your product launch.
STAT – Upending drug industry financing
This article looks at how Vibe Bio CEO, Alok Tayi, is seeking to upend drug industry financing.
Endpoint News – Parents become drug developers to save their children’s lives
Endpoint News addressed how parents of children with rare disease are challenging the status quo in drug development.
